Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Quarterly research and development expenses increased as Attovia advanced its clinical and preclinical programs.

Rhea-AI Summary

Attovia Therapeutics (ATTO) reported third-quarter financial results and Phase 1b findings showing itch reduction with ATTO-1310 after a single dose. At Week 12, 82% of treated chronic-pruritus patients achieved at least a four-point itch reduction versus 22% with placebo. In high-itch atopic dermatitis, 44% achieved that reduction at Week 4 versus 25% with placebo, with response sustained through Week 12.

Third-quarter net loss widened to $22.271 million from $13.779 million a year earlier. Cash, cash equivalents and marketable securities totaled $395.939 million at September 30, 2026; Attovia expects funding to last into 2030. Its August IPO raised approximately $332.4 million in gross proceeds. The company expects two ATTO-1310 Phase 2 trials and Phase 1 trials for ATTO-2306 and ATTO-1091 to begin in the first half of 2027.

20 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointAugust IPO raised approximately $332.4 million gross, before underwriting discounts, commissions and other offering expenses. 48% of market cap
• Moderate pointATTO-1310 achieved four-point itch reductions in 82% versus 22% on placebo at Week 12 in chronic pruritus; nominal p<0.01.
• Minor pointChronic-pruritus patients reporting no or minimal itch reached 47% versus 0% on placebo at Week 12; p<0.05.
• Minor pointHigh-itch atopic dermatitis four-point itch responses reached 44% versus 25% on placebo at Week 4, sustained through Week 12.
• Minor pointHigh-itch atopic dermatitis patients reporting no or minimal itch reached 28% (5/18) versus 13% (1/8) at Week 12.

15 minor points

• Minor pointAtopic dermatitis skin-severity improvement of at least 75% reached 44% versus approximately 13% on placebo through Week 12.
• Minor pointClear or almost clear skin responses reached 39% versus approximately 13% on placebo through Week 12.
• Minor pointATTO-1310 was generally well tolerated in healthy volunteers and patients, with low immunogenicity.
• Minor point. Forward-looking: it has not happened yet and may not happen.ATTO-1310 suppressed circulating IL-31 by approximately 95% through Week 12; Attovia sees potential for quarterly dosing.
• Minor point. Forward-looking: it has not happened yet and may not happen.ATTO-1310 Phase 2 trials in unknown-origin chronic pruritus and high-itch atopic dermatitis are expected in first-half 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.ATTO-1310 cholestatic-pruritus Phase 1b trial began in China; topline results are expected in second-half 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.ATTO-2306 Phase 1 initiation is expected in first-half 2027, with studies supporting an investigational application ongoing.
• Minor point. Forward-looking: it has not happened yet and may not happen.ATTO-1091 Phase 1 initiation is expected in first-half 2027, with studies supporting an investigational application ongoing.
• Minor pointCash and securities increased to $395.939 million at September 30, 2026, from $152.268 million at December 31, 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.Attovia expects September 30, 2026 cash and securities to fund operations into 2030.
• Minor pointNine-month collaboration revenue rose to $450,000 from $360,000 for the periods ended September 30.
• Minor pointThird-quarter interest income rose to $2.787 million from $1.855 million; nine-month income rose to $5.254 million from $5.022 million.
• Minor pointThird-quarter loss per share narrowed to $0.76 from $3.44; nine-month loss per share narrowed to $4.86 from $11.18.
• Minor pointTotal liabilities declined to $14.083 million at September 30, 2026, from $15.103 million at December 31, 2025.
• Minor pointStockholders’ equity reached $397.741 million at September 30, 2026, versus a $107.436 million deficit at December 31, 2025.

Negative

• Moderate pointThird-quarter net loss widened to $22.271 million from $13.779 million a year earlier.
• Minor pointNine-month net loss widened to $61.614 million from $43.369 million a year earlier.
• Minor pointThird-quarter collaboration revenue fell to zero from $360,000 a year earlier.
• Minor pointThird-quarter research and development expenses rose to $20.290 million from $12.317 million a year earlier.
• Minor pointNine-month research and development expenses rose to $55.982 million from $37.761 million a year earlier.

2 minor points

• Minor pointThird-quarter general and administrative expenses rose to $4.734 million from $3.645 million a year earlier.
• Minor pointNine-month general and administrative expenses rose to $11.250 million from $10.925 million a year earlier.

News Explained

Attovia has initiated a Phase 1b trial in China of ATTO-1310 for cholestatic pruritus associated with primary biliary cholangitis or primary sclerosing cholangitis; topline results are expected in the second half of 2027, placing this study in active clinical development.

Key Figures

CP PP-NRS4 response: 82% vs. 22% with placebo; nominal p<0.01 CP PP-NRS<2 response: 47% vs. 0% with placebo; p<0.05 High-itch AD PP-NRS4 response: 44% vs. 25% with placebo +4 more

CP PP-NRS4 response

82% vs. 22% with placebo; nominal p<0.01

Week 12, Phase 1b

CP PP-NRS<2 response

47% vs. 0% with placebo; p<0.05

Week 12, Phase 1b

High-itch AD PP-NRS4 response

44% vs. 25% with placebo

Week 4, Phase 1b

EASI-75 response

44% vs. approximately 13% with placebo

High-itch AD through Week 12

Cash and marketable securities

$395.9 million

As of September 30, 2026; expected to fund operations into 2030

Collaboration revenue

$0 vs. $0.4 million

Third quarter 2026 vs. third quarter 2025

Net loss

$22.3 million vs. $13.8 million

Third quarter 2026 vs. third quarter 2025

Previous Earnings Reports

1 past event · Latest: Sep 02

Same Type 1 event

1. Sep 02

   Phase 1b results

   24h Move

   +4.6%

   Prior quarter reported preliminary ATTO-1310 proof of concept and Phase 2 starts in 1H 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

easi-75, pharmacokinetic, pharmacodynamic, subcutaneous, +2 more

6 terms

easi-75 medical

"achieving at least a 75% improvement on the Eczema Area and Severity Index (EASI-75)"

EASI-75 is a clinical result meaning a patient has achieved at least a 75% improvement on the Eczema Area and Severity Index, a standardized score that combines how much skin is affected and how severe the symptoms are. Investors watch EASI-75 because it serves as a clear, widely accepted benchmark of a drug’s effectiveness in eczema trials—like a pass/fail meter—so higher EASI-75 rates improve a therapy’s approval odds and commercial prospects.

pharmacokinetic medical

"Phase 1a safety, pharmacokinetic, and pharmacodynamic data in healthy volunteers"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"Phase 1a safety, pharmacokinetic, and pharmacodynamic data in healthy volunteers"

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

subcutaneous medical

"A single subcutaneous (SC) dose of ATTO-1310 led to rapid, sustained suppression"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

bispecific antibody medical

"a long-acting bispecific antibody targeting IL-31 and IL-13"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

trispecific medical

"a next-generation ATTOBODY-based trispecific designed to target TL1A"

A trispecific drug is a single engineered molecule designed to attach to three different biological targets at once, like a three-pronged tool that can grip multiple pieces simultaneously. For investors, trispecifics can offer greater therapeutic precision or combined effects compared with single-target drugs, potentially boosting value if successful, but they also bring higher scientific complexity, development cost and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)

Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritus of unknown origin (CPUO) and high-itch AD expected in 1H 2027

Initiation of Phase 1 trials for ATTO-2306 and ATTO-1091 expected in 1H 2027

Cash, cash equivalents, and marketable securities of approximately $395.9 million as of September 30, 2026, expected to provide cash runway into 2030

SAN CARLOS, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“During the third quarter, we continued to execute on our clinical development priorities, positioning Attovia for an exciting and potentially transformative year ahead,” said Tao Fu, Founder and Chief Executive Officer of Attovia. “The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile. These results reinforce our confidence in ATTO-1310’s potential to become a next-generation IL-31 therapy for millions of patients suffering from chronic itch conditions. We have also made significant progress in preparing for our two Phase 2 ATTUNE trials in CPUO and high-itch AD, both of which remain on track to initiate in the first half of 2027. In parallel, we continue to advance ATTO-2306 and ATTO-1091 toward clinical development, positioning Attovia for multiple important milestones in 2027.”

Recent Pipeline Highlights and Upcoming Milestones

ATTO-1310 for pruritic diseases: a next-generation, half-life extended ATTOBODY-based Fc-fusion protein targeting the itch cytokine IL-31.

• Hosted a virtual KOL and ATTO-1310 clinical development update featuring leading experts Brian Kim, MD, MTR, FAAD, and Jonathan Silverberg, MD, PhD, MPH.
• Announced positive 12-week topline results from the Phase 1b study of ATTO-1310 in patients with CP and high-itch AD following a single dose of ATTO-1310. Results demonstrated the following:
  • CP: a rapid, clinically meaningful reduction in itch of ≥4 points on the Peak Pruritus Numerical Rating Scale (PP-NRS4) was observed, with 82% of ATTO-1310-treated patients achieving PP-NRS4 vs. 22% with placebo (nominal p<0.01) at Week 12. A similar trend was observed in patients who were itch-free or nearly itch-free (PP-NRS<2), with 47% of ATTO-1310-treated patients achieving a response at Week 12 vs. 0% with placebo (p<0.05).
  • High-itch AD: in patients with high-itch AD, a rapid reduction in itch was observed, with 44% of ATTO-1310-treated patients achieving PP-NRS4 at Week 4 vs. 25% with placebo. The treatment response was sustained through Week 12. In the more stringent itch-free or nearly itch-free (PP-NRS<2) analysis, 28% (5/18) of ATTO-1310-treated patients achieved a response at Week 12 vs. 13% (1/8) with placebo.
    • Additionally, improvements in skin lesions were observed through Week 12, with 44% of ATTO-1310-treated patients achieving at least a 75% improvement on the Eczema Area and Severity Index (EASI-75) and 39% achieving clear or almost clear skin on the validated Investigator Global Assessment (vIGA 0/1), compared with approximately 13% on placebo for both measures.
  • Safety and pharmacology: ATTO-1310 was generally well tolerated in both healthy volunteers (HVs) and patients, and demonstrated low immunogenicity. A single subcutaneous (SC) dose of ATTO-1310 led to rapid, sustained suppression of circulating IL-31 (approximately 95%) through Week 12, supporting the potential for quarterly dosing.
• Advanced preparations for the two Phase 2 ATTUNE trials in CPUO and high-itch AD, with both trials on track to initiate in the first half of 2027.
  • The Phase 2 ATTUNE-CPUO trial design has been aligned with the U.S. Food and Drug Administration (FDA), and site activation is underway.
  • The Phase 2 ATTUNE-AD trial protocol has been finalized, and site selection has been initiated.
• Presented three posters highlighting clinical and translational data for ATTO-1310 at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and Fall Clinical Dermatology Conference 2026. Presentations included Phase 1a safety, pharmacokinetic, and pharmacodynamic data in healthy volunteers, new data supporting the key role of IL-31 across pruritic skin diseases, and interim Phase 1b results demonstrating early clinical activity in patients with CP and high-itch AD.
• Initiated the Phase 1b trial in patients with cholestatic pruritus associated with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) in China, with topline results expected in the second half of 2027.
  
  

ATTO-2306 for AD and other immune-mediated skin diseases: a highly potent, half-life extended ATTOBODY-based bispecific antibody targeting IL-31 and IL-13.

• Presented a poster highlighting new preclinical data at the Fall Clinical Dermatology Conference 2026, demonstrating potent inhibition of IL-13 and IL-31 signaling, significant reductions in pruritus and inflammation in preclinical models, and an extended half-life in nonhuman primates.
• IND-enabling activities are ongoing, with Phase 1 trial initiation expected in the first half of 2027.
  
  

ATTO-1091 for inflammatory bowel disease: a next-generation ATTOBODY-based trispecific designed to target TL1A, IL-23p19, and integrin α4β7.

• IND-enabling activities are ongoing, with Phase 1 trial initiation expected in the first half of 2027.
  
  

Corporate Highlights

• Completed an upsized initial public offering in August 2026, raising approximately $332.4 million in aggregate gross proceeds, before deducting underwriting discounts, commissions, and other offering expenses. Attovia’s common stock began trading on the Nasdaq Global Market on August 5, 2026, under the ticker symbol “ATTO.”
  
  

Third Quarter Financial Results

Revenue: There was no collaboration revenue for the third quarter of 2026, compared to $0.4 million in the third quarter of 2025 attributable to research and development services provided under the EndPath RadioTherapeutics license agreement.

Cash Position: Cash, cash equivalents, and marketable securities were $395.9 million as of September 30, 2026, compared to $152.3 million as of December 31, 2025. The Company expects that its cash, cash equivalents, and marketable securities as of September 30, 2026, will be sufficient to fund its operations into 2030.

Research & Development (R&D) Expenses: Research and development expenses were $20.3 million for the third quarter of 2026, compared to $12.3 million for the third quarter of 2025. The increase in R&D expenses was primarily driven by clinical and manufacturing costs to advance ATTO-1310 toward completion of its Phase 1 trial, and manufacturing and preclinical costs to advance ATTO-2306 and ATTO-1091 in IND-enabling activities.

General & Administrative (G&A) Expenses: General and administrative expenses were $4.7 million for the third quarter of 2026, compared to $3.6 million for the third quarter of 2025. The increase in G&A expenses was primarily due to higher personnel costs to support the Company’s growth and higher administrative and facility-related expenses.

Net Loss: Net loss was $22.3 million for the third quarter of 2026, as compared to $13.8 million for the third quarter of 2025.

About Attovia Therapeutics, Inc.

Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’-gated bispecific immune cell survival blockers and multispecifics.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the Company’s future plans and prospects; any expectations regarding the safety or efficacy of ATTO-1310, ATTO-2306, and ATTO-1091, and other candidates under development; the ability of such candidates to treat their indications; the planned timing of the Company’s clinical trials, data results, and further development of its product candidates; the sufficiency of the Company’s current cash, cash equivalents, and marketable securities to fund its operations; and the Company’s expected cash runway. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will,” “predict,” and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance, or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the Company’s ability to advance its product candidates and obtain regulatory approval of and ultimately commercialize such product candidates, the timing and results of preclinical studies and clinical trials, the risk that topline or interim results from clinical trials, including results based on a limited number of patients, may not be predictive of final results or of results of later clinical trials, the Company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic and geopolitical conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, public health crises, and geopolitical conflicts. Further information on potential risk factors that could affect the Company’s business and its financial results is detailed under the heading “Risk Factors” included in the documents the Company files from time to time with the U.S. Securities and Exchange Commission. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release, and Attovia undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor and Media Contacts

Attovia Therapeutics
Heather Armstrong
Head of Investor Relations
ir@attovia.com

PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com

Attovia Therapeutics, Inc.
Condensed Consolidated Balance Sheets – Selected Data (unaudited)
(in thousands)

		September 30, 2026				December 31, 2025
Cash, cash equivalents, and marketable securities		$	395,939			$	152,268
Total assets			411,824				165,893
Total liabilities			14,083				15,103
Total stockholders' equity (deficit)			397,741				(107,436	)

Attovia Therapeutics, Inc.
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue
Collaboration revenue		$	—			$	360			$	450			$	360
Total revenue			—				360				450				360
Operating expenses
Research and development			20,290				12,317				55,982				37,761
General and administrative			4,734				3,645				11,250				10,925
Total operating expenses			25,024				15,962				67,232				48,686
Loss from operations			(25,024	)			(15,602	)			(66,782	)			(48,326	)
Other income (expense)
Interest income			2,787				1,855				5,254				5,022
Change in fair value of preferred stock tranche liability			—				—				—				(170	)
Other income (expense), net			(34	)			(32	)			(86	)			105
Total other income (expense), net			2,753				1,823				5,168				4,957
Net loss		$	(22,271	)		$	(13,779	)		$	(61,614	)		$	(43,369	)
Less: Accretion of redeemable convertible preferred stock to its redemption value			—				—				—				(271	)
Net loss attributable to common stockholders		$	(22,271	)		$	(13,779	)		$	(61,614	)		$	(43,640	)
Net loss per share attributable to common stockholders, basic and diluted		$	(0.76	)		$	(3.44	)		$	(4.86	)		$	(11.18	)
Weighted-average common shares outstanding, basic and diluted			29,370,016				4,004,963				12,679,296				3,902,967

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Attovia’s ATTO-1310 Phase 1b trial show for chronic pruritus?

At Week 12 after a single dose, 82% of ATTO-1310-treated chronic-pruritus patients achieved at least a four-point itch reduction, versus 22% with placebo, with nominal p<0.01. Patients reporting no or minimal itch reached 47% versus 0% with placebo, with p<0.05.

How long does Attovia expect its cash to fund operations?

Attovia expects its September 30, 2026 cash, cash equivalents and marketable securities to fund operations into 2030. Those holdings totaled $395.939 million, compared with $152.268 million at December 31, 2025.

What preparations has Attovia completed for the ATTO-1310 Phase 2 ATTUNE trials?

The ATTUNE-CPUO trial design has been aligned with the FDA and site activation is underway; the ATTUNE-AD protocol has been finalized and site selection has begun. Attovia expects both trials to start in the first half of 2027.

Which patients are enrolled in Attovia’s ATTO-1310 cholestatic-pruritus trial?

The Phase 1b trial in China includes patients with cholestatic pruritus associated with primary biliary cholangitis or primary sclerosing cholangitis. The trial has begun, and Attovia expects topline results in the second half of 2027.